Table 1.
Patient and treatment characteristics (n = 69)
| Characteristic | De novo irradiation (n = 42) no. patients (%) | Reirradiation (n = 27) no. patients (%) |
|---|---|---|
| Age (y) | ||
| Median | 55.9 | 58.1 |
| Range | 15.7-82.1 | 31.3-88.0 |
| Sex | ||
| Male | 29 (69.0%) | 17 (63.9%) |
| Female | 13 (31.0%) | 10 (37.0%) |
| ECOG PS | ||
| 0 | 30 (71.4%) | 19 (70.4%) |
| ≥1 | 12 (28.6%) | 8 (29.6%) |
| Smoking status | ||
| Nonsmoker | 26 (64.3%) | 14 (51.9%) |
| Former/current smoker | 15 (35.7%) | 13 (48.1%) |
| Primary site | ||
| Nasal cavity | 21 (55.3%) | 14 (60.9%) |
| Maxillary sinus | 10 (26.3%) | 5 (21.7%) |
| Ethmoid sinus | 7 (18.4%) | 3 (13.0%) |
| Sphenoid sinus | 0 | 1 (4.3%) |
| Not specified | 4 | 4 |
| Histology | ||
| Squamous cell carcinoma | 15 (35.7%) | 11 (40.7%) |
| Adenoid cystic carcinoma | 8 (19.0%) | 6 (22.2%) |
| Esthesioneuroblastoma | 10 (23.8%) | 4 (14.8%) |
| Adenocarcinoma | 5 (11.9%) | 4 (14.8%) |
| Small cell neuroendocrine | 2 (4.8%) | 1 (3.7%) |
| SNUC | 2 (4.8%) | 1 (3.7%) |
| T stage | ||
| T1 | 5 (11.9%) | 0 |
| T2 | 6 (14.3%) | 3 (11.1%) |
| T3 | 6 (14.3%) | 7 (25.9%) |
| T4a | 7 (16.7%) | 9 (33.3%) |
| T4b | 18 (42.9%) | 8 (29.6%) |
| N stage | ||
| N0 | 37 (88.1%) | 19 (70.4%) |
| N1-N2 | 5 (11.9%) | 8 (29.6%) |
| Stage | ||
| I | 5 (11.9%) | 0 |
| II | 6 (14.3%) | 2 (7.4%) |
| III | 6 (14.3%) | 6 (22.2%) |
| IVA | 7 (16.7%) | 11 (40.7%) |
| IVB | 16 (38.1%) | 8 (29.6%) |
| IVC | 2 (4.8%) | 0 |
| Proton beam therapy target | ||
| Primary site/surgical bed | 39 (92.9%) | 23 (92.0%) |
| Primary site + neck | 2 (4.8%) | 2 (8.0%) |
| Not specified | 1 | 2 |
| Concurrent chemotherapy | ||
| Yes | 16 (38.1%) | 10 (37.0%) |
| No | 26 (61.9%) | 17 (63.0%) |
Abbreviations: ECOG PS = Eastern Cooperative Oncology Group performance status; SNUC = sinonasal undifferentiated carcinoma.